id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10172 R37171 |
Blotière (Phenobarbital) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
2.51 [0.14;44.28] C excluded (control group) |
0/80 7/2,997 | 7 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10042 R36307 |
Blotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 3.49 [0.22;56.34] C | 0/80 3,371/1,875,733 | 3,371 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9151 R31458 |
Tomson (Phenobarbital), 2018 | Hypospadias | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.43 [0.17;11.89] C | 1/294 6/2,514 | 7 | 294 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9107 R31282 |
Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 | Hypospadias | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 23.72 [0.96;584.27] C | 1/199 0/1,562 | 1 | 199 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9124 R31347 |
Bànhidy (Phenobarbital), 2011 | Hypospadias | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 3.80 [0.06;243.53] C | 0/ 3/13 | 3 | 0 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9101 R31185 |
D'Souza (Phenobarbital) (Controls unexposed, disease free), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
17.57 [0.30;1024.08] C excluded (control group) |
0/4 0/62 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9102 R31214 |
D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.14 [0.03;131.94] C | 0/4 0/8 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9172 R31576 |
Van der Pol (Phenobarbital) (Controls unexposed, disease free), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
4.74 [0.09;251.42] C excluded (control group) |
0/12 0/55 | 0 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9173 R31601 |
Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.87 [0.03;100.54] C | 0/12 0/22 | 0 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 3.10 [0.88;10.93] | 3,382 | 589 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital) (Controls unexposed NOS) (Mixed indications; 2: Phenobarbital; 3: Phenobarbital) (Controls exposed to Lamotrigine, sick; 4: Phenobarbital; 5: Phenobarbital) (Controls unexposed, sick; 6: Phenobarbital) (Controls unexposed, sick;
Asymetry test p-value = 0.5492 (by Egger's regression)
slope=0.0206 (1.7570); intercept=0.7284 (1.1148); t=0.6534; p=0.5492
excluded 9101, 9172, 10172